Novartis (SIX Swiss: NOVN and NYSE: NVS) has suffered a staggering loss exceeding $30 billion in market capitalization after announcing the failure of its neuromuscular candidate delpacibart etedesiran (del-desiran) in a Phase III trial. This setback not only impacts the company financially but also raises serious concerns among major investors regarding Novartis’ strategic direction and acquisition decisions.
Investor dissatisfaction has been vocalized by prominent stakeholders such as Artisan Partners, whose managing director M. David Samra criticized the board’s oversight of acquisitions, particularly the $12 billion buyout of Avidity Partners. Samra’s remarks underscore a growing sentiment that the company’s acquisition strategy has not delivered the expected value, with the recent trial failure further exacerbating trust issues. The del-desiran trial, designed to target myotonic dystrophy type 1, missed its primary endpoint, leading to a significant drop in Novartis’ share price, marking its worst one-day selloff since March 2020.
The implications of this trial failure extend beyond immediate financial losses, as it has prompted analysts to revise sales forecasts for del-desiran and raised questions about Novartis’ future pipeline and strategic acquisitions. As the company navigates this challenging landscape, the need for a reassessment of its approach to mergers and acquisitions becomes increasingly critical to restore investor confidence and ensure sustainable growth.
Start your 7-day trial and see what the database can do →
